Taylor A. Brown is from the Washington State University Elson S. Floyd College of Medicine, Spokane. Dr. Khachemoune is from the Department of Dermatology, Brooklyn VA Medical Center, New York, and SUNY Downstate Dermatology Service, Brooklyn.
Cutis. 2024 Aug;114(2):E43-E52. doi: 10.12788/cutis.1085.
Prurigo nodularis (PN) manifests with highly pruritic lesions that negatively impact patient quality of life. Due to the variability in manifestation, hypertrophic lichen planus, pemphigoid nodularis, and neurotic excoriations tend to mimic PN. The pathophysiology of PN is believed to be due to interactions in the neural and immune pathways causing the release of proinflammatory and pruritogenic cytokines. Dermatologic and systemic conditions, including atopic dermatitis and chronic kidney disease, accompany PN diagnoses. Patients with moderate to severe or recalcitrant PN may benefit from dupilumab, the first medication approved by the US Food and Drug Administration (FDA) to treat PN. Here, we provide an updated review of PN with a focus on its pathophysiology, histologic findings, and current treatment options.
结节性痒疹表现为高度瘙痒的病变，对患者的生活质量产生负面影响。由于表现的多样性，肥厚性扁平苔藓、大疱性类天疱疮结节和神经性搔抓倾向于模仿结节性痒疹。结节性痒疹的病理生理学被认为是由于神经和免疫途径的相互作用导致促炎和瘙痒细胞因子的释放。结节性痒疹常伴有皮肤病学和系统性疾病，包括特应性皮炎和慢性肾脏病。中重度或难治性结节性痒疹患者可能受益于度普利尤单抗，这是美国食品和药物管理局（FDA）批准的第一种治疗结节性痒疹的药物。在这里，我们提供了一个关于结节性痒疹的最新综述，重点介绍其病理生理学、组织学发现和当前的治疗选择。
